Floatz logo

Capecitabine

ERBB3 Gene Mutation

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the ERBB3 Gene Mutation cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
M.D. Anderson Cancer Center
Phase 1CC
Neratinib
M.D. Anderson Cancer Center
Phase 1CC
Everolimus
M.D. Anderson Cancer Center
Phase 1CC
Vinorelbine
M.D. Anderson Cancer Center
Phase 1CC
Palbociclib
M.D. Anderson Cancer Center
Phase 1CC
Trastuzumab Emtansine
M.D. Anderson Cancer Center
Phase 1CC
gsk1120212
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →